1.	Phase III Randomized Study of Monoclonal Antibody B43.13 in Patients With Stage III or IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Adenocarcinoma Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0211008, UNITHER-OVA-Gy-17(A), NCT00050375
2.	Phase IIB Randomized Study of OvaRex Monoclonal Antibody B43.13 as Post Chemotherapy Consolidation in Patients With Stage III or IV Ovarian Epithelial, Tubal, or Peritoneal Adenocarcinoma (Summary Last Modified 04/2000) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ALTAREX-OVA-Gy-07, ALTAREX-961452, ALTAREX-OVA-Gy-06, NCI-V98-1488, NCT00003634
3.	Phase II Randomized Study of OvaRex Monoclonal Antibody B43.13 in Patients with Epithelial Adenocarcinoma of the Ovary, Fallopian Tube, or Peritoneum and Elevated Serum CA 125, But Without Other Evidence of Disease (Summary Last Modified 07/2000) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ALTAREX-OVA-Gy-10, OU-08111, NCT00004064
4.	Randomized Pilot Study of Consolidation Therapy Comprising Adjuvant Oregovomab With Versus Without Cyclophosphamide in Patients With Stage III or IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Adenocarcinoma That Responded to Second-Line Taxane/Platinum-Based Therapy Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: GOG-0243, GOG-0243, NCT00551265